Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials.

Abstract In 2014, our research network was involved in the evaluation of favipiravir, an anti-Influenza polymerase inhibitor, against Ebola virus. In this review we discuss how mathematical modelling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a non-human […]

Click here to view original web page at www.ncbi.nlm.nih.gov

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.